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ABSTRACT: Pulmonary arterial hypertension (PAH) is an increasingly recognized complication of HIV dis-
ease associated with significant morbidity and mortality. The prevalence of PAH is estimated to be 0.5%
in HIV-infected patients compared to the 0.02% in non HIV-infected patients. A beneficial effect of anti-
retroviral therapy on the course of HIV-related PAH has not been clearly established. Bosentan, a dual en-
dothelin-1 receptor antagonist, may be an effective approach to treatment of PAH in HIV-infected patients.
We report a first case of a successful therapy with bosentan in an HIV-infected patient treated with fos-
amprenavir/ritonavir based-regimen.
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INTRODUCTION
Pulmonary arterial hypertension (PAH) is a distinct sub-
group of pulmonary hypertension that comprises herita-
ble, drug and toxin induced, idiopathic and secondary
forms associated with specific diseases such as human
immunodeficiency virus (HIV) infection, connective tis-
sue disease, and portal hypertension. PAH is defined by
a mean pulmonary artery pressure at rest ≥25 mm Hg in
presence of a pulmonary capillary wedge pressure ≤15
mm Hg1.
HIV-infected patients have an increased risk of PAH
compared to general population. Mechanism underlying
the increased risk of PAH in HIV is still not clearly elu-
cidated. The prevalence of PAH is estimated to be 0.5%
in HIV-infected patients compared to the 0.02% in HIV
seronegative people2. PAH onset is independent from
age, race, duration of HIV disease (expressed as the time
from diagnosis of HIV infection to time of PAH diagno-
sis), and ongoing highly active antiretroviral therapy
(HAART), while resulted to be associated with intra-
venous drug use3. There was no overall difference with
regard to lymphocyte T CD4+ cells count, but the pro-
portion of patients with a lymphocyte T CD4+ count of
less than 200/mm3 was significantly higher in those with
PAH3.
PAH prevalence remained unchanged even after in-
troduction of HAART, being right heart failure a major
cause of death in this population3.
Two orally active endothelin receptor antagonists are
currently approved for the treatment of PAH: the dual re-
ceptor-antagonist bosentan and the most selective ET(A)
receptor-antagonist ambrisentan. These drugs have the
advantage of oral formulation, and have shown efficacy
on improving exercise capacity, quality of life and hemo-
dynamics in HIV infected patients with PAH, both in
short-term and long term4.
However, limited data regarding both the impact of
HAART in the disease pathogenesis and progression5 and
the patterns of drug-drug interactions between HAART
and compounds used for the treatment of PAH are avail-
able6,7. We report a case of a successful therapy for PAH
with bosentan in a HIV-infected patient in stable fosam-
prenavir/ritonavir (fAPV/r) based-regimen.
mated pulmonary pressures (PAPs 55 mmHg, PAP mean
(PAPm) 34 mmHg), signs of initial right ventricular (RV)
dilation (33 mm) and septal pressure overload. Accord-
ingly, right heart catheterization confirmed severe pul-
monary hypertension with high pulmonary vascular
resistances and preserved right ventricular function (PAPs
95/35 mmHg, PAPm 57 mmHg, Wedge 14 mmHg, Car-
diac Index 3.15 L/min/m2, pulmonary vascular resistance
(PVR) 635 dynes/sec/cm-5). N-terminal prohormone of
brain natriuretic peptide (NT-proBNP) was 131 ng/L.
Treatment with ambrisentan was started but discontinued
after 1 week for clinically confirmed hypersensitivity. 
After a short wash-out, treatment with bosentan was
introduced at the dosage of 62.5 mg twice-daily, without
any modification of HAART. Due to previous intolerance
and potential drug-drug interaction with a boosted protease
inhibitor (PI), a slower 8-week titration of the endothelin
receptor antagonist was planned; two weeks after bosentan
initiation, measurement of fAPV therapeutic drug moni-
toring (TDM) by a validated high-performance liquid
chromatography/photodiode array detection (HPLC-
PDA)8 was performed at the end of dosing interval (T0)
and 2 hours post drug intake (T2). (Figure 1). Since fAPV
plasma concentrations were in the expected range and no
side effects were reported, bosentan dose was increased to
125 mg twice-daily. fAPV TDM was repeated one month
after bosentan titration (Figure 1, dashed line). For both
dosages, fAPV plasma exposure resulted to be higher in
the second measurement as compared to the first (1390
ng/ml vs 1492 ng/ml at T0 and 4232 ng/ml vs 5036 ng/ml
at T2). Tolerability of both therapies and a discrete benefit
on both exercise capacity (+28m at 6-minute walk test)
and symptoms were confirmed. 
At 12 months of follow-up, HIV-RNA was persist-
ently below <50 copies/ml and lymphocyte CD4+ cell
count was 514 cells/mL. Laboratory data excluded he-
patic toxicity and the patient did not report any further
episode of hemoptysis nor other symptoms related to
PAH.
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CASE REPORT 
A 43 year-old Caucasian woman was diagnosed with
HIV-1 and hepatitis C virus co-infections in 1989. 
Her past medical history included intravenous drug
use from 1982 to 1986. She started HAART in 1998 with
zidovudine + lamivudine and nevirapine with poor ad-
herence in the first years. After pregnancy (2002) and the
birth of an HIV-negative child, the patient improved ad-
herence to the same therapy, and CD4+ cell reached a
stable count of more 500 cell/mmc with HIV-RNA per-
sistently below 50 copies/ml.
In 2007, the patient complained of hemoptysis and
mild dyspnea, at this time she was receiving tenofovir
(300 mg) plus emtricitabine (200 mg) once daily and
twice-daily fAPV/r (100/700 mg); HIV-RNA was below
50 copies/ml, and a lymphocyte T CD4+ was 515
cell/mmc (25%).
Computer Tomography (CT) scan showed pulmonary
micro nodules, in absence of fibrosis or signs of pul-
monary embolism; a moderate (40 mm) ectasia of the
trunk and both left (27 mm) and right (25 mm) branches
of pulmonary artery (PA) were also reported. Microbio-
logical exams of sputum and bronchoalveolar lavage
were negative, including detection of mycobacteria.
Esophagogastroscopy was unremarkable. Presence of an
increased estimated systolic pulmonary pressure (PAPs
65 mmHg) was noticed at echocardiography; however,
due to progressive spontaneous clinical improvement and
absence of cardiac dilatation or right ventricular function
impairment signs, no further test was recommended at
that time. In the following years the patient continued
HAART and regular follow-up without any symptom.
In January 2011 dyspnea and asthenia reappeared,
along with episodes of hemoptysis. A new pulmonary CT
scan showed progression of the arterial dilatation (PA
trunk 42 mm, left PA 30 mm, right PA 30 mm). She was
thus referred to the pulmonary hypertension unit of our
institution; echocardiography highlighted increased esti-
Figure 1. Fosamprenavir concentrations values in the course of different dosage of bosentan.  T0: Fosamprenavir Ctrough before admin-
istration; T2: Fosamprenavir C 2 hours after administration.
_____ Continuos line plasma fosamprenavir concentrations when bosentan dose was 62,5 mg twice daily
- - - - - Dashed line plasma fosamprenavir concentrations when bosentan dose was 125 mg twice daily
Eight months later, follow-up right heart catheteriza-
tion confirmed satisfactory response to first line therapy
(PAPs 70 mmHg; PAP diastolic 5 mmHg; PAPm 42
mmHg; Cardiac Index 3.72 L/min/m2; PVR 421
dynes/sec/cm-5).
DISCUSSION
This is the first case report of co-administration of bosen-
tan and fAPV/r in the clinical setting. TDM of fAPV con-
centration with two different dosages of bosentan showed
a moderate increase of the PI concentration with no clin-
ical implication. In fact, no modification of HAART ef-
ficacy and tolerability has been observed in the follow
up. Bosentan has been estimated to have both CYP-3A4
and CYP2C9-inducing properties9, and could be there-
fore related to a theoretical decrease of concomitant PI
concentrations, known substrates of CYP3A4. In our
HIV-infected patients, as opposite, a possible dose-re-
lated effect of bosentan in increasing fAPV concentration
was observed (Figure 1). Although in a single case no
conclusion can be drawn, our follow up confirmed the
maintenance of adequate plasma exposure of fAPV. Un-
fortunately, measurements of bosentan plasma levels
were not available. However, optimal tolerability of the
treatment and absence of bosentan toxicity in the follow
up suggested that the theoretical increase of bosentan
concentration associated to concomitant boosted PI10 was
not clinically significant in our patient. 
PAH is a relevant comorbidity in HIV-infected pa-
tients, requiring clinical awareness and specific treat-
ment. Due to the substantial lack of clinical information
on pharmacological compatibility of endothelin receptor
antagonist and HAART, facing a high potential for drug-
drug interaction, our case supports the safe and effective
coadministration of bosentan and fAPV boosted by ri-
tonavir.
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